SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: 2013 Report on the International Acute Myeloid Leukemia (AML) Market - Opportunity Analysis and Forecasts to 2017

[January 22, 2014]

Research and Markets: 2013 Report on the International Acute Myeloid Leukemia (AML) Market - Opportunity Analysis and Forecasts to 2017

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/5g6pvq/opportunityanalyze) has announced the addition of the "2013 Report on the International Acute Myeloid Leukemia (AML) Market - Opportunity Analysis and Forecasts to 2017" report to their offering.

Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cytarabine-based chemotherapy, which can often achieve remission. However, th majority of patients relapse, and survival rates are grim. There are clear unmet needs for treatments that can prolong the overall survival of these patients, but drug manufacturers have struggled to gain regulatory approval for new therapies.


Key Questions Answered

  • Which AML patients have the greatest unmet needs?
  • What are the R&D strategies drug makers are pursuing in the AML space?
  • Why has it been so difficult for Pharma to develop successful therapies for AML?
  • How are players aiming to circumvent difficulties that have historically plagued AML drug development?
  • What are the most promising pipeline agents for AML? How do their clinical and commercial attributes compare to one another?
  • What opportunities will remain following the launch of these pipeline agents?
  • Do KOLs see a role for targeted therapies and immunotherapies in the treatment of AML?

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs Assessment and Opportunity Analysis

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

For more information visit http://www.researchandmarkets.com/research/5g6pvq/opportunityanalyze


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.